The majority of the studies performed with the anti-human CD4 antibody MAX.16H5 focused on the treatment of autoimmune diseases such as RA, SLE, IDB and JCA and revealed striking results that identified the MAX.16H5 antibody as a promising alternative for conventional therapeutics. This evidence concerns the gene CD4 and systemic lupus erythematosus.